drugset / Trial / NCT05407519
A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
Phase 2
Unknown
40 enrolled
Anhui Provincial Hospital
First Affiliated Hospital Xi'an Jiaotong University · collabFirst Affiliated Hospital of Guangxi Medical University · collabHenan Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, multi-center, single arm study to evaluate the efficacy and safety of tislelizumab combined with sitravatinib as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after curative resection.
Timeline
- Start
- 2022-07-25
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sitravatinib | Small molecule | 100 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |